Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (91-100 of 349) with videos related to

Pageof 35
Sort By:
Journal of Cancer Research and Clinical Oncology|March 23, 2019
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinomaJang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, et al.
Translational Lung Cancer Research|January 11, 2024
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 18, 2016
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyJi Hyun Lee, Ho Yun Lee, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II StudyHyun Ae Jung, Sehhoon Park, Yoon-La Choi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALKJong-Mu Sun, Yoon-La Choi, Jae-Kyung Won, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
Pleural epithelioid hemangioendothelioma harboring CAMTA1 rearrangementSang Yun Ha, In Ho Choi, Joungho Han, et al.
BMC Cancer|October 22, 2025
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational studyJi Eun Shin, Sehhoon Park, Hyun Ae Jung, et al.
Cancer Research and Treatment|May 23, 2023
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene RearrangementYoungkyung Jeon, Hyun Ae Jung, Sehhoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II TrialJong-Mu Sun, Jin Seok Ahn, Sin-Ho Jung, et al.
Expert Opinion on Pharmacotherapy|August 2, 2020
Evaluating entrectinib as a treatment option for non-small cell lung cancerJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
Pageof 35

Showing results (91-100 of 349) with videos related to

Sort By:
Pageof 35
Journal of Cancer Research and Clinical Oncology|March 23, 2019
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinomaJang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, et al.
Translational Lung Cancer Research|January 11, 2024
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 18, 2016
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyJi Hyun Lee, Ho Yun Lee, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2022
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II StudyHyun Ae Jung, Sehhoon Park, Yoon-La Choi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALKJong-Mu Sun, Yoon-La Choi, Jae-Kyung Won, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
Pleural epithelioid hemangioendothelioma harboring CAMTA1 rearrangementSang Yun Ha, In Ho Choi, Joungho Han, et al.
BMC Cancer|October 22, 2025
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational studyJi Eun Shin, Sehhoon Park, Hyun Ae Jung, et al.
Cancer Research and Treatment|May 23, 2023
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene RearrangementYoungkyung Jeon, Hyun Ae Jung, Sehhoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II TrialJong-Mu Sun, Jin Seok Ahn, Sin-Ho Jung, et al.
Expert Opinion on Pharmacotherapy|August 2, 2020
Evaluating entrectinib as a treatment option for non-small cell lung cancerJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
Pageof 35